NEXEL

NEXEL is a biotechnology company founded in 2012 with patented stem cell technology. Their mission is to "create a better world" by supporting innovative research worldwide through the provision of high-quality stem cell-derived cell products. In 2018, NEXEL launched Cardiosight®-S, which has since been validated on multiple platforms as a functional population of pure hiPSC-derived cardiomyocytes. Other product lines include Hepatosight®-S (iPS-derived hepatocytes) and Neurosight®-S (iPS-derived neurons).